NASDAQ
0.60USD
-0.05 (-7.32%)
We have scored 5 news catalysts on Rani Therapeutics Holdings, Inc. (RANI) over the past 12 months. The biggest single-day move next to one of them came Oct 22, 2026, when RANI closed −7.3%: “Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances”. Coverage across the window leans positive (average ticker sentiment +0.70). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
39.5M
P/E
—
EPS
—
Beta
0.71
52W range
0.603-3.87
Day range
0.60–0.66
Open
0.66
Prev close
0.65
Volume
687.4K
Avg volume
714.2K
Dividend
0.00
IPO
2021-07-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Rani Therapeutics Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for RANI: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
